Literature DB >> 27631529

[Update palliative pain therapy].

R Rolke1, S Rolke2, S Hiddemann3, M Mücke4,5,6, H Cuhls4, L Radbruch4, F Elsner3, V Peuckmann-Post3.   

Abstract

Cancer pain and pain associated with non-neoplastic diseases can be associated with pain mechanisms, such as a peripheral or central sensitization or deafferentation. The clarification allows indirect conclusions about the underlying mechanisms based on clinical signs, such as allodynia or hyperalgesia. Non-opioid analgesics are the basis of cancer pain therapy according to the World Health Organization (WHO) pain ladder. In the case of severe cancer pain, treatment can be escalated directly from level 1 to level 3. Opioids are highly effective for the treatment of cancer pain even with a neuropathic component, which can occur in up to 40 % of cases as amixed pain syndrome. Coanalgesics represent a valuable therapeutic adjunct for better pain control and can address treatment of comorbidities, such as anxiety, depression and sleep disorders. When liver and/or renal function is reduced, the dosage of many drugs has to be adapted. Treatment of multimorbid or critically ill patients with opioids and antidepressants/anticonvulsants requires consideration of numerous possible pharmacodynamic and pharmacokinetic interactions.

Entities:  

Keywords:  Anticonvulsants; Antidepressive agents; Neuropathic pain; Opioids; Pain, neoplasms

Mesh:

Substances:

Year:  2016        PMID: 27631529     DOI: 10.1007/s00108-016-0126-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  26 in total

1.  Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor.

Authors:  K Kassahun; I S McIntosh; M Shou; D J Walsh; C Rodeheffer; D E Slaughter; L A Geer; R A Halpin; N Agrawal; A D Rodrigues
Journal:  Drug Metab Dispos       Date:  2001-06       Impact factor: 3.922

Review 2.  Opioids in renal failure and dialysis patients.

Authors:  Mervyn Dean
Journal:  J Pain Symptom Manage       Date:  2004-11       Impact factor: 3.612

Review 3.  Usefulness and limitations of quantitative sensory testing: clinical and research application in neuropathic pain states.

Authors:  Per Hansson; Miroslav Backonja; Didier Bouhassira
Journal:  Pain       Date:  2007-04-23       Impact factor: 6.961

Review 4.  The Kyoto protocol of IASP Basic Pain Terminology.

Authors:  John D Loeser; Rolf-Detlef Treede
Journal:  Pain       Date:  2008-06-25       Impact factor: 6.961

Review 5.  Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain.

Authors:  S G Waxman; T R Cummins; S Dib-Hajj; J Fjell; J A Black
Journal:  Muscle Nerve       Date:  1999-09       Impact factor: 3.217

6.  Long-term treatment of cancer pain with transdermal fentanyl.

Authors:  B Donner; M Zenz; M Strumpf; M Raber
Journal:  J Pain Symptom Manage       Date:  1998-03       Impact factor: 3.612

Review 7.  Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors.

Authors:  Elana M Nelson; Ann M Philbrick
Journal:  Ann Pharmacother       Date:  2012-12-04       Impact factor: 3.154

Review 8.  Buprenorphine in the treatment of opioid dependence.

Authors:  Eugen Davids; Markus Gastpar
Journal:  Eur Neuropsychopharmacol       Date:  2004-05       Impact factor: 4.600

Review 9.  Methadone.

Authors:  Shalini Chhabra; Janet Bull
Journal:  Am J Hosp Palliat Care       Date:  2008 Apr-May       Impact factor: 2.500

10.  Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics.

Authors:  R K Portenoy; M A Southam; S K Gupta; J Lapin; M Layman; C E Inturrisi; K M Foley
Journal:  Anesthesiology       Date:  1993-01       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.